WUXI06:BKK
Wuxi Biologics (Cayman) Inc. KKPS DR
5,20 THB
0,00%
(0,00) 1 d.
15. 10., 16:40:00 GMT+7 · THB
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre WUXI06…
Otvoriť
5,25 THB
Vysoká
5,35 THB
Nízka
5,05 THB
Trh. kap.
198,43 mld.
Priem. obj.
93,60 tis.
Objem
288,50 tis.
Max. za 52 týž.
6,25 THB
Min. za 52 týž.
3,02 THB
Akcie v obehu
4,12 mld.
Počet zamestnancov
15 tis.
Otvoriť
5,25 THB
Vysoká
5,35 THB
Nízka
5,05 THB
Trh. kap.
198,43 mld.
Priem. obj.
93,60 tis.
Objem
288,50 tis.
Max. za 52 týž.
6,25 THB
Min. za 52 týž.
3,02 THB
Akcie v obehu
4,12 mld.
Počet zamestnancov
15 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
MarketBeat
·
pred 15 minútami
Plains All American Pipeline Lp (NASDAQ:PAA) Stock Rated "Hold" by Sell-Side Brokerages
BigGo Finance
·
pred 27 minútami
AI investment logic shifts and chip sell-off hit markets: Nasdaq tumbles 2.15%, Philadelphia Semiconductor Index plunges 3.83%
KITV
·
pred 1 hodinou
Nasdaq sinks more than 2% as investors raise questions about AI debt
MarketWatch
·
pred 10 hodinami
Don’t buy this dip: Several signs suggest there’s more pain ahead for tech stocks
Profil
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Informácie o subjekte Wuxi Biologics (Cayman) Inc. KKPS DR
Generálny riaditeľZhisheng Chen
Zamestnanci14,7 tis.
Dátum založenia2010
Hlavné sídlo-
Odvetvie-